Last reviewed · How we verify
Intravenous anesthetic, propofol
Propofol, an intravenous anesthetic, is a marketed product developed by University Hospital, Basel, Switzerland. The key composition patent for propofol is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Intravenous anesthetic, propofol |
|---|---|
| Also known as | Diprivan,, Diprovan |
| Sponsor | University Hospital, Basel, Switzerland |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- The Effect of Intravenous Versus Volatile Anesthesia on Postoperative Cognitive Dysfunction in Elderly Patients (NA)
- Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery (PHASE4)
- Equivalent MAC in General Anesthesia
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Comparative Impacts of Two Anesthesia Methods on Peripheral Tissue Oxygenation in the Upper Limb (NA)
- Reduction of Muscle Catabolism Through Brain Activation in Burn Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: